What to watch with CYP2D6 and Blutzucker?

CYP2D6 is primarily a drug-metabolizing enzyme with no strong direct link to blood glucose regulation. Most evidence concerns its role in metabolizing medications (e.g., beta-blockers, antidepressants, opioids) that may indirectly affect glucose homeostasis through weight changes or insulin sensitivity. However, direct genetic associations between CYP2D6 variants and fasting glucose, HbA1c, or diabetes risk are weak and not clinically actionable. Consumer DNA tests reporting CYP2D6 metabolizer status (poor, intermediate, extensive, ultrarapid) should not be used to predict blood sugar issues. Standard glycemic markers (fasting glucose, HbA1c, insulin) and lifestyle factors are far more relevant. If you take drugs metabolized by CYP2D6, your phenotype may influence drug efficacy and side effects – discuss with a physician. The evidence for a CYP2D6–blood sugar link is mechanistic/unclear at best.